Swiss Life Asset Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-9,027
Closed -$917K 1543
2025
Q4
$917K Buy
9,027
+506
+6% +$40.6K ﹤0.01% 659
2025
Q3
$466K Buy
8,521
+469
+6% +$23.4K ﹤0.01% 738
2025
Q2
$428K Sell
8,052
-8,221
-51% -$418K ﹤0.01% 681
2025
Q1
$704K Buy
16,273
+2,926
+22% +$148K 0.01% 644
2024
Q4
$749K Buy
13,347
+6,899
+107% +$429K 0.01% 626
2024
Q3
$439K Buy
+6,448
New +$364K 0.01% 554
2024
Q1
Sell
-5,666
Closed -$420K 574
2023
Q4
$420K Sell
5,666
-1,662
-23% -$109K 0.01% 593
2023
Q3
$499K Sell
7,328
-37,130
-84% -$3.15M 0.01% 577
2023
Q2
$4.17M Buy
44,458
+3,538
+9% +$276K 0.06% 352
2023
Q1
$2.77M Buy
+40,920
New +$2.63M 0.04% 435
2022
Q3
Sell
-3,947
Closed -$156K 606
2022
Q2
$156K Buy
+3,947
New +$211K ﹤0.01% 604

Other funds holding EXAS

Swiss Life Asset Management's EXAS Position: Q1 2026 in Review

Swiss Life Asset Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 9,027 shares — an estimated $917K sold.

Swiss Life Asset Management first reported a position in EXAS in Q2 2022 and held it in 11 quarters. The position peaked at $4.17M in Q2 2023. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Swiss Life Asset Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 9,027 Exact Sciences shares in Q1 2026, an estimated $917K.
  • Swiss Life Asset Management first reported a position in Exact Sciences in Q2 2022 and held it in 11 quarters.
  • Swiss Life Asset Management's Exact Sciences position peaked at $4.17M in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Swiss Life Asset Management's 13F filing for Q1 2026, filed 14 May 2026.